Published in J Periodontol on November 01, 1999
Growth factor delivery for oral and periodontal tissue engineering. Expert Opin Drug Deliv (2006) 1.24
Retracted Platelet-rich plasma in periodontal defect treatment after extraction of impacted mandibular third molars. Natl J Maxillofac Surg (2012) 1.08
Biomaterial delivery of morphogens to mimic the natural healing cascade in bone. Adv Drug Deliv Rev (2012) 1.07
Growth factors regulate expression of mineral associated genes in cementoblasts. J Periodontol (2000) 0.92
Gene expression pattern during osteogenic differentiation of human periodontal ligament cells in vitro. J Periodontal Implant Sci (2011) 0.86
Tissue engineering for bone regeneration and osseointegration in the oral cavity. Dent Mater (2015) 0.85
Molecular characterization of spontaneous and growth-factor-augmented chondrogenesis in periosteum-bone tissue transferred into a joint. Histochem Cell Biol (2005) 0.79
Enamel matrix proteins exhibit growth factor activity: A review of evidence at the cellular and molecular levels. Exp Ther Med (2015) 0.78
Periodontal regeneration using platelet-derived growth factor in infrabony defects: a series of three cases. Case Rep Dent (2013) 0.77
Platelet-rich plasma in the treatment of Class II furcation defects: a histometrical study in dogs. J Appl Oral Sci (2012) 0.76
Alveolar bone graft with Platelet Rich Plasma in cleft alveolus. J Oral Biol Craniofac Res (2013) 0.75
Osteostimulatory effect of bone grafts on fibroblast cultures. J Nat Sci Biol Med (2015) 0.75
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology (2000) 6.42
Spectra of spontaneous mutations in Escherichia coli strains defective in mismatch correction: the nature of in vivo DNA replication errors. Proc Natl Acad Sci U S A (1987) 4.35
Spontaneous mutation in the Escherichia coli lacI gene. Genetics (1991) 2.53
A return on investment evaluation of the Citibank, N.A., health management program. Am J Health Promot (1999) 2.20
Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol (2001) 1.95
Blockade of autocrine stimulation in simian sarcoma virus-transformed cells reverses down-regulation of platelet-derived growth factor receptors. Proc Natl Acad Sci U S A (1984) 1.80
Escherichia coli mutT mutator effect during in vitro DNA synthesis. Enhanced A.G replicational errors. J Biol Chem (1987) 1.68
Mutants of Escherichia coli with increased fidelity of DNA replication. Genetics (1993) 1.66
Genetic requirements and mutational specificity of the Escherichia coli SOS mutator activity. J Bacteriol (1997) 1.64
The relationship between modifiable health risks and group-level health care expenditures. Health Enhancement Research Organization (HERO) Research Committee. Am J Health Promot (2000) 1.63
The C-C (6-4) UV photoproduct is mutagenic in Escherichia coli. Proc Natl Acad Sci U S A (1986) 1.61
1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol (1997) 1.61
Mechanisms of ultraviolet-induced mutation. Mutational spectra in the Escherichia coli lacI gene for a wild-type and an excision-repair-deficient strain. J Mol Biol (1987) 1.57
The role of psychologists in the treatment, management, and prevention of chronic mental illness. Am Psychol (1993) 1.52
The relationship between modifiable health risks and health care expenditures. An analysis of the multi-employer HERO health risk and cost database. J Occup Environ Med (1998) 1.50
Regulation of cementoblast gene expression by inorganic phosphate in vitro. Calcif Tissue Int (2006) 1.35
An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A (2003) 1.33
Transcription-repair coupling determines the strandedness of ultraviolet mutagenesis in Escherichia coli. Proc Natl Acad Sci U S A (1992) 1.31
Molecular and cell biology of cementum. Periodontol 2000 (2000) 1.27
Isolation, characterization and immunolocalization of a 53-kDal dentin sialoprotein (DSP). Matrix (1992) 1.27
Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys (2000) 1.26
TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements. Exp Cell Res (2001) 1.25
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol (1998) 1.22
Position paper: sonic and ultrasonic scalers in periodontics. Research, Science and Therapy Committee of the American Academy of Periodontology. J Periodontol (2000) 1.22
Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol (2000) 1.18
Cementum engineering with three-dimensional polymer scaffolds. J Biomed Mater Res A (2003) 1.16
Expression of bone associated markers by tooth root lining cells, in situ and in vitro. Bone (1997) 1.15
Hypersensitivity of Escherichia coli Delta(uvrB-bio) mutants to 6-hydroxylaminopurine and other base analogs is due to a defect in molybdenum cofactor biosynthesis. J Bacteriol (2000) 1.14
Employing a transgenic animal model to obtain cementoblasts in vitro. J Periodontol (2000) 1.12
Pancuronium infusion for neuromuscular block in children in the pediatric intensive care unit. Anesth Analg (1995) 1.11
The progressive ankylosis protein regulates cementum apposition and extracellular matrix composition. Cells Tissues Organs (2011) 1.11
Cementum: a phosphate-sensitive tissue. J Dent Res (2002) 1.10
Controlling for systematic selection in retrospective analyses: an application to fluoxetine and sertraline prescribing in the United Kingdom. Value Health (2006) 1.09
Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res (2000) 1.09
Tooth root dentin mineralization defects in a mouse model of hypophosphatasia. J Bone Miner Res (2013) 1.09
Effects of citric acid on diseased root surfaces. J Periodontal Res (1978) 1.08
Assessment of early continence recovery after radical prostatectomy: patient reported symptoms and impairment. J Urol (2001) 1.06
Clodronate kinetics and bioavailability. Clin Pharmacol Ther (1982) 1.05
Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res (1999) 1.04
Monolithic tetracycline-containing fibers for controlled delivery to periodontal pockets. J Periodontol (1983) 1.03
Immortalized cementoblasts and periodontal ligament cells in culture. Bone (1999) 1.02
Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS PharmSciTech (2000) 1.02
Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate. J Pharm Sci (2000) 1.01
Phosphate regulates osteopontin gene transcription. J Dent Res (2009) 1.00
Inhibition of bioprosthetic heart valve calcification with aminodiphosphonate covalently bound to residual aldehyde groups. Ann Thorac Surg (1988) 0.99
Deficiency in acellular cementum and periodontal attachment in bsp null mice. J Dent Res (2012) 0.99
Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol (2001) 0.98
Combination of osteoinductive bone proteins differentiates mesenchymal C3H/10T1/2 cells specifically to the cartilage lineage. J Cell Biochem (1997) 0.98
Parathyroid hormone protects against periodontitis-associated bone loss. J Dent Res (2003) 0.97
Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm (2000) 0.97
Effects of GnRH agonist (leuprolide) on reproduction and behaviour in female wapiti (Cervus elaphus nelsoni). Reprod Suppl (2002) 0.97
Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem (1995) 0.97
X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model. Cell Death Differ (2008) 0.97
Role of two mineral-associated adhesion molecules, osteopontin and bone sialoprotein, during cementogenesis. Connect Tissue Res (1995) 0.97
The effect of enamel matrix protein derivative on follicle cells in vitro. J Periodontol (2001) 0.95
Matrix gamma-carboxyglutamic acid protein is a key regulator of PTH-mediated inhibition of mineralization in MC3T3-E1 osteoblast-like cells. Endocrinology (2001) 0.95
Human periodontal cells initiate mineral-like nodules in vitro. J Periodontol (1991) 0.94
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology (2005) 0.94
Evidence that a non-RGD domain in rat osteopontin is involved in cell attachment. J Bone Miner Res (1993) 0.94
Effects of nonsurgical periodontal therapy on periodontitis in humans. A review. J Clin Periodontol (1983) 0.92
Regulation of cementoblast function by P. gingivalis lipopolysaccharide via TLR2. J Dent Res (2006) 0.92
A two-step intervention of increase mammography among women aged 65 and older. Am J Public Health (1997) 0.92
Extracellular phosphate alters cementoblast gene expression. J Dent Res (2006) 0.92
Growth factors regulate expression of mineral associated genes in cementoblasts. J Periodontol (2000) 0.92
Dentin sialoprotein (DSP) transcripts: developmentally-sustained expression in odontoblasts and transient expression in pre-ameloblasts. Eur J Oral Sci (1997) 0.92
Bone sialoprotein is localized to the root surface during cementogenesis. J Bone Miner Res (1994) 0.92
Effect of bone proteins on human prostate cancer cell lines in vitro. Prostate (1998) 0.91
Expression of extracellular matrix proteins in human periodontal ligament cells during mineralization in vitro. J Periodontol (1997) 0.91
Connective tissue-associated proteins in crevicular fluid: potential markers for periodontal diseases. J Periodontol (1989) 0.91
Commercially-prepared allograft material has biological activity in vitro. J Periodontol (1995) 0.91
Structure and mechanical properties of Ank/Ank mutant mouse dental tissues--an animal model for studying periodontal regeneration. Arch Oral Biol (2009) 0.91
Response of immortalized murine cementoblasts/periodontal ligament cells to parathyroid hormone and parathyroid hormone-related protein in vitro. Arch Oral Biol (2000) 0.91
Compounded PHOSPHO1/ALPL deficiencies reduce dentin mineralization. J Dent Res (2013) 0.90
Development and regeneration of the periodontium: parallels and contrasts. Periodontol 2000 (1999) 0.90
Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. J Cell Biochem (2000) 0.89
Vitamin D represses dentin matrix protein 1 in cementoblasts and osteocytes. J Dent Res (2013) 0.88
Aberrant cementum phenotype associated with the hypophosphatemic hyp mouse. J Periodontol (2009) 0.88
Regenerating the periodontium: is there a magic formula? Orthod Craniofac Res (2005) 0.87
Cementoblast gene expression is regulated by Porphyromonas gingivalis lipopolysaccharide partially via toll-like receptor-4/MD-2. J Dent Res (2004) 0.87
In vivo evaluation of a resorbable osteoinductive composite as a graft substitute for lumbar spinal fusion. J Spinal Disord (1997) 0.87
Wnt/β-catenin pathway regulates bone morphogenetic protein (BMP2)-mediated differentiation of dental follicle cells. J Periodontal Res (2011) 0.86
Periodontal pocket treatment in beagle dogs using subgingival doxycycline from a biodegradable system. I. Initial clinical responses. J Periodontol (1996) 0.86
Lead inhibits secretion of osteonectin/SPARC without significantly altering collagen or Hsp47 production in osteoblast-like ROS 17/2.8 cells. Toxicol Appl Pharmacol (1992) 0.86
Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J Natl Cancer Inst (2000) 0.85
Parathyroid hormone-related protein regulates extracellular matrix gene expression in cementoblasts and inhibits cementoblast-mediated mineralization in vitro. J Bone Miner Res (2000) 0.85
The drug delivery and biomaterial attributes of the ATRIGEL technology in the treatment of periodontal disease. Expert Opin Investig Drugs (1998) 0.85
Physiology of bone: mineral compartment proteins as candidates for environmental perturbation by lead. Environ Health Perspect (1991) 0.85
Periodontal regeneration in naturally occurring Class II furcation defects in beagle dogs after guided tissue regeneration with bioabsorbable barriers. J Periodontol (1997) 0.84
Diarrhea and methemoglobinemia in an infant. Pediatr Emerg Care (2000) 0.84
Expression of bone sialoprotein mRNA by cells lining the mouse tooth root during cementogenesis. Arch Oral Biol (1997) 0.84
Effects of endogenous and exogenous prostaglandin E2 on the proliferation and differentiation of a mouse cementoblast cell line (OCCM-30). J Periodontol (2006) 0.83
A composite of natural coral, collagen, bone protein and basic fibroblast growth factor tested in a rat subcutaneous model. Ann Chir Gynaecol Suppl (1993) 0.83
Measurement of cardiac output by cine computed tomography. Am J Cardiol (1985) 0.82
Agents with periodontal regenerative potential regulate cell-mediated collagen lattice contraction in vitro. J Dent Res (1996) 0.82
Noggin gene delivery inhibits cementoblast-induced mineralization. Connect Tissue Res (2004) 0.82
Biologic modifiers in periodontal regeneration. Dent Clin North Am (1998) 0.82
Coordinate expression of OPN and associated receptors during monocyte/macrophage differentiation of HL-60 cells. J Cell Physiol (1998) 0.81
Parathyroid hormone-related protein down-regulates bone sialoprotein gene expression in cementoblasts: role of the protein kinase A pathway. Endocrinology (2000) 0.81
Promotion of HL-60 cell differentiation by 1,25-dihydroxyvitamin D3 regulation of protein kinase C levels and activity. Biochem Pharmacol (1997) 0.81